Two other studies are ongoing, namely KEYVIBE-003 [115] (NCT04738487), with a pembrolizumab/vibostolimab regimen versus pembrolizumab alone in the first-line treatment for patients diagnosed with mNSCLC with tumor PD-L1 > 1% (TPS), with OS as the primary endpoint, and KEYVIBE-007 [116] (NCT05226598) with a pembrolizumab/vibostolimab regimen combined with a platinum-based doublet versus the standard first-line regimen of pembrolizumab and a platinum-based doublet for systemically naive mNSCLC, regardless of PD-L1 status, and with OS as the primary endpoint. This evidence concerns the gene CD274 and neoplasm.